CCO Independent Conference Highlights of the 2023 ASH Annual Meeting *

Review slidesets, on-demand webcasts, and expert analyses of key studies from the 2023 ASH Annual Meeting. 

Share

Program Content

Activities

Key Studies From ASH 2023
An Expert’s Guide to ASH 2023: Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

Activities

Conference to clinic ASH 2023
Conference to Clinic: Expert Analysis of the 2023 ASH Top Abstracts
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 01, 2024

Expires: January 31, 2025

9 Capsule Summary Slidesets

Activities

Oral AAA in ND APL
All-Oral Arsenic Trioxide–Based Induction in Newly Diagnosed Acute Promyelocytic Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

COMMANDS Full Analysis
COMMANDS: Full Analysis of Phase III Trial of Luspatercept vs Epoetin alfa for ESA-Naive, Transfusion-Dependent, Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

ASCEND-CML
ASCEND-CML: Phase II Trial of Frontline Asciminib in Patients With CP-CML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Quizartinib, Ven, Dec in FLT3 ITD Mutated AML
Phase I/II Trial of Quizartinib, Venetoclax, and Decitabine in FLT3-ITD–Mutated AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Retrospective STOP-VEN Study
STOP-VEN: Discontinuation of Venetoclax + Azacitidine for Patients With AML in Remission at Time of Treatment Interruption
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

STIMULUS-AML2
STIMULUS-AML2: Preliminary Safety of Sabatolimab Monotherapy in Patients With MRD+ AML After AlloSCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

Revumenib for Acute Leukemia
AUGMENT-101: Phase II Study of Revumenib for R/R KMT2Ar Acute Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

QuANTUM-First  MRD Analysis
Phase III QuANTUM-First: Prognostic Value of FLT3-ITD–Specific MRD Clearance at Induction/Consolidation Using Chemotherapy With or Without Quizartinib in Patients With AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2023

IMerge Subgroup Analysis
Phase III IMerge Subgroup Analysis: Imetelstat for Achieving Transfusion Independence in ESA R/R or Ineligible Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

Activities

ASH 2023 Data in Leukemias and MDS
Conference to Clinic: Leukemias and Myelodysplastic Syndromes
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 10, 2024

ASH 2023: Leukemias and MDS
Key Studies in Leukemias and Myelodysplastic Syndromes: Independent Conference Coverage of ASH 2023
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 06, 2024

Expires: March 05, 2025

13 Capsule Summary Slidesets

Activities

AN + AD in Early cHL
Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine in Early-Stage Classical Hodgkin Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

1L Mosunetuzumab SC for FL
Mosunetuzumab SC as First-line Therapy for Patients With High Tumor Burden Follicular Lymphoma: Results of a Phase II Study
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

EPCORE NHL 5
EPCORE NHL-5: Results From Arm 1 of a Phase Ib/II Trial Evaluating SC Epcoritamab + Lenalidomide in Relapsed/Refractory DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

TRANSCEND CLL 004 Update
TRANSCEND CLL 004: 24-Mo Follow-up of Lisocabtagene Maraleucel in Relapsed/Refractory CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

BOVen in 1L TP53mut MCL
BOVen: Phase II Trial of Zanubrutinib, Obinutuzmab, and Venetoclax in Treatment-Naive TP53-Mutated Mantle Cell Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

VALENTINE-PTCL01
VALENTINE-PTCL01: Primary Results of Phase II Trial of Valemetostat Tosylate in Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

ELM-2 Final Analysis
ELM-2: Final Analysis From Phase II Trial of Odronextamab in Relapsed/Refractory DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

ELEVATE TN: 6 Yr Update
ELEVATE-TN 6-Yr Update: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

ELM-2 Exploratory ctDNA Analysis
ELM-2 Exploratory Analysis: Association Between ctDNA-Assessed Measurable Residual Disease Status and PFS With Odronextamab in R/R FL and DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

SWOG S1826
SWOG S1826: Nivolumab-AVD vs BV-AVD in Older Patients (Aged ≥60 Years) With Advanced Stage Classic Hodgkin Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

SYMPATICO
SYMPATICO: Phase III Trial of Ibrutinib + Venetoclax vs Ibrutinib + Placebo for Patients With R/R Mantle Cell Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

TRANSCEND FL at ASH 2023
TRANSCEND FL: Lisocabtagene Maraleucel as Second-Line Therapy for Patients With High-Risk R/R Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

ELARA 3-Year Follow-up
Phase II ELARA: 3-Year Follow-up of Tisagenlecleucel in R/R Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Activities

Lymphoma Updates 2023
Conference to Clinic: Lymphoma Updates 2023
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 11, 2024

ASH 2023: Lymphomas and CLL
Key Studies in Lymphomas and CLL: Independent Coverage of ASH 2023
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 06, 2024

Expires: March 05, 2025

7 Capsule Summary Slidesets

Activities

LINKER-MM1 Update
LINKER-MM1 Update: Phase I/II Trial of Anti-BCMAxCD3 Bispecific Antibody Linvoseltamab in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

IsKia EMN24 in ND MM
IsKia EMN24: Phase III Trial of IsaKRd vs KRd in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

CENTAURUS Final Analysis
CENTAURUS: Final Analysis of Phase II Study With Daratumumab Monotherapy in Intermediate- or High-Risk Smoldering MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

MonumenTAL-1 Modified Dosing
MonumenTAL-1: Impact of Dose Modification on Safety and Efficacy of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2023

PERSEUS Primary Analysis
PERSEUS: Primary Analysis of Phase III Trial With VRd ± Daratumumab in Patients With Newly Diagnosed Multiple Myeloma Eligible for ASCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

DRVd vs RVd Real World
D-RVd vs RVd for Newly Diagnosed Transplant-Eligible Patients With Multiple Myeloma: Real-world Outcomes
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

VenDd in t(11;14) RR MM
Phase I/II Trial of Venetoclax/Dara/Dex (VenDd) vs Bortezomib/Dara/Dex (DVd) in t(11;14) R/R MM: Updated Analysis of MRD Negativity
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

Activities

Multiple Myeloma
Conference to Clinic: Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 09, 2024

ASH 2023 Multiple Myeloma
Conference to Clinic: Expert Analysis of the Top Multiple Myeloma Abstracts From the 2023 ASH Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 07, 2024

Expires: March 06, 2025

5 Capsule Summary Slidesets

Activities

TRANSFORM 1
TRANSFORM-1: Phase III Trial of Navitoclax + Ruxolitinib vs Placebo + Ruxolitinib in Previously Untreated Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

MANIFEST 2
MANIFEST-2: Phase III Trial of Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib for JAK Inhibitor–Naive Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Bomedemstat in ET
Phase IIb Trial of LSD1 Inhibitor Bomedemstat in Patients With Essential Thrombocythemia Resistant or Intolerant to Standard Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

RuxoBEAT
RuxoBEAT: Interim Results From a Randomized Phase IIb Study of Ruxolitinib Vs BAT as First-line Therapy in High-Risk Polycythemia Vera
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

Bomedemstat Plus Ruxolitinib for MF
Phase II Study of Bomedemstat Plus Ruxolitinib for Patients With Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Activities

MPN Updates 2023
Conference to Clinic: Myeloproliferative Neoplasm Updates 2023
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 11, 2024

ASH 2023: MPNs
Key Studies in Myeloproliferative Neoplasms: Independent Conference Coverage of ASH 2023
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 06, 2024

Expires: March 05, 2025

6 Capsule Summary Slidesets

Activities

Sutimlimab in CAD Safety Analysis
Pooled Post Hoc Analysis of Safety Outcomes From Phase III CARDINAL and CADENZA Trials of Sutimlimab in Cold Agglutinin Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

REACH: Hydroxyurea for SCA
REACH: Long-term Analysis of Dose-Optimized Hydroxyurea for Treatment of Pediatric Patients With Sickle Cell Anemia in Sub-Saharan Africa
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Lovo-cel in SCD Pooled Analysis
Pooled Analysis of Phase I/II and Phase III Trials of Lovotibeglogene Autotemcel Gene Therapy in Patients With Sickle Cell Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

BMT CTN 1507 RIC BMT SCD
BMT CTN 1507: Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults With Severe Sickle Cell Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

APPLY-PNH Final Results
APPLY-PNH Final 48-Wk Results: Phase III Trial of Iptacopan Monotherapy in Patients With PNH and Residual Anemia With Anti-C5 Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

PNH ALPHA Study
ALPHA: Phase III Long-term Data for Ravulizumab or Eculizumab With Add-on Danicopan or Placebo in Patients With PNH and cs-EVH
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Activities

Nonmalignant Hematology Disorders
Conference to Clinic: Nonmalignant Hematology Disorders
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 08, 2024

ASH 2023: Nonmalignant Hematology
Key Studies in Nonmalignant Hematology Disorders: Independent Conference Coverage of ASH 2023
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2024

Expires: February 21, 2025

Faculty

cover img faculity

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

cover img faculity

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

cover img faculity

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.